Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
- Authors: Bakulev A.L.1, Samtsov A.V.2, Kubanov A.A.3, Khairutdinov V.R.2, Kokhan M.M.4, Artemyeva A.V.5, Derbin S.I.5, Chernyaeva E.V.5, Ivanov R.A.5
-
Affiliations:
- Saratov State Medical Universit y named after V. I. Razumovsky, Ministr y of Health of the Russian Federation
- S. M. Kirov Militar y Medical Academy, Ministr y of Defence of the Russian Federation
- State Research Center of Dermatovenereology and Cosmetology, Ministr y of Health of the Russian Federation
- Ural Research Institute for Dermatovenerology and Immunopatology
- BIOCAD
- Issue: Vol 95, No 3 (2019)
- Pages: 54-64
- Section: DRUG TREATMENT IN DERMATOVENEROLOGY
- Submitted: 02.10.2019
- Accepted: 02.10.2019
- Published: 02.06.2019
- URL: https://vestnikdv.ru/jour/article/view/499
- DOI: https://doi.org/10.25208/0042-4609-2019-95-3-54-64
- ID: 499
Cite item